Axsome Therapeutics, Inc. $AXSM Shares Bought by UBS Group AG

Key Points

• UBS Group AG increased its stake in Axsome by 67.2% in Q4 to 355,318 shares (about 0.70% of the company), worth roughly $64.9 million.
• Insiders sold 67,878 shares totaling about $11.12 million last quarter (including COO Mark Jacobson's 35,378-share sale), even though company insiders still hold 22.3% of the stock.
• Axsome reported Q1 revenue of $191.2M, beating consensus and up ~57% YoY but missed EPS (-$1.26 vs. -$0.85); the company also logged regulatory and pipeline progress (Auvelity approval and an NDA submission) while analysts maintain a Moderate Buy consensus with an average price target of ~$235.79.

UBS Group AG raised its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 67.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 355,318 shares of the company's stock after purchasing an additional 142,867 shares during the period. UBS Group AG owned about 0.70% of Axsome Therapeutics worth $64,895,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Allworth Financial LP grew its holdings in Axsome Therapeutics by 6.6% in the third quarter. Allworth Financial LP now owns 1,442 shares of the company's stock valued at $175,000 after purchasing an additional 89 shares during the last quarter. Meridian Wealth Management LLC grew its holdings in Axsome Therapeutics by 0.5% in the third quarter. Meridian Wealth Management LLC now owns 22,124 shares of the company's stock valued at $2,687,000 after purchasing an additional 103 shares during the last quarter. GAMMA Investing LLC grew its holdings in Axsome Therapeutics by 65.4% in the fourth quarter. GAMMA Investing LLC now owns 268 shares of the company's stock valued at $49,000 after purchasing an additional 106 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Axsome Therapeutics by 6.1% during the third quarter. PNC Financial Services Group Inc. now owns 1,856 shares of the company's stock worth $225,000 after buying an additional 107 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D increased its position in Axsome Therapeutics by 0.6% during the third quarter. State of New Jersey Common Pension Fund D now owns 18,158 shares of the company's stock worth $2,205,000 after buying an additional 109 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company's stock.

Insider Activity

In other news, COO Mark L. Jacobson sold 35,378 shares of Axsome Therapeutics stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $161.88, for a total value of $5,726,990.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Ari Maizel sold 7,500 shares of Axsome Therapeutics stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $182.42, for a total value of $1,368,150.00. Following the completion of the sale, the insider directly owned 7,500 shares of the company's stock, valued at approximately $1,368,150. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 67,878 shares of company stock valued at $11,122,891 over the last quarter. Company insiders own 22.30% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on AXSM shares. Needham & Company LLC raised their price target on Axsome Therapeutics from $225.00 to $255.00 and gave the stock a "buy" rating in a research report on Friday. Piper Sandler reissued an "overweight" rating and set a $258.00 price target on shares of Axsome Therapeutics in a research report on Monday. Oppenheimer set a $280.00 price target on Axsome Therapeutics in a research report on Monday. Royal Bank Of Canada raised their price target on Axsome Therapeutics from $219.00 to $222.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 24th. Finally, Guggenheim reissued a "buy" rating and set a $260.00 price target on shares of Axsome Therapeutics in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $235.79.

Axsome Therapeutics Price Performance

Shares of NASDAQ:AXSM opened at $224.03 on Tuesday. The company has a market cap of $11.52 billion, a P/E ratio of -60.71 and a beta of 0.59. The company has a quick ratio of 1.48, a current ratio of 1.55 and a debt-to-equity ratio of 1.38. Axsome Therapeutics, Inc. has a 52 week low of $96.09 and a 52 week high of $234.29. The business has a fifty day simple moving average of $170.95 and a 200-day simple moving average of $162.68.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings data on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.41). The business had revenue of $191.20 million during the quarter, compared to analysts' expectations of $191.10 million. Axsome Therapeutics had a negative net margin of 28.69% and a negative return on equity of 232.61%. The firm's quarterly revenue was up 57.4% compared to the same quarter last year. Equities research analysts forecast that Axsome Therapeutics, Inc. will post -1.06 EPS for the current year.

More Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Q1 revenue beat and strong year-over-year growth: Net product revenue was $191.2M (vs. $191.1M consensus) and up ~57% year-over-year, driven by Auvelity ($153.2M) and Sunosi ($33.9M). This supports continued commercial momentum across core products. Read More.
• Positive Sentiment: Regulatory and pipeline progress: Auvelity received an approval for agitation associated with dementia due to Alzheimer’s disease, and Axsome submitted an NDA for AXS‑12 (cataplexy). The company also added AXS‑20 (PDE10A inhibitor) to the pipeline—these expand addressable markets and future revenue potential. Read More.
• Positive Sentiment: Analyst/broker tone and investor engagement: Broker consensus is a “Moderate Buy,” and management will be participating in multiple investor conferences in May (BofA, fireside chat, etc.), which can boost visibility and help reprice expectations. Read More. Read More.
• Neutral Sentiment: Company events and disclosures: Management hosted a conference call and published a slide deck and transcript; analysts will parse details on unit trends and cost trajectory during conference appearances. Read More.
• Negative Sentiment: EPS miss and continued losses: Reported EPS was a loss of $1.26 vs. consensus -$0.85 (miss), and the company remains unprofitable with negative margins and ROE metrics—this leaves valuation sensitive to execution. Read More.
• Negative Sentiment: Mixed product trends flagged by analysts: Despite strong YoY growth, some analysts note sequential declines in Auvelity and Sunosi sales and call management’s peak revenue targets ambitious, which could limit upside if sustained. Read More.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome's pipeline includes several late-stage and approved product candidates.

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.